Octreotide depot formulation with constantly high exposure levels

Details for Australian Patent Application No. 2009336718 (hide)

Owner Novartis AG

Inventors Ahlheim, Markus; Petersen, Holger

Agent Davies Collison Cave

Pub. Number AU-A-2009336718

PCT Pub. Number WO2010/079047

Priority 08171712.6 15.12.08 EP

Filing date 14 December 2009

Wipo publication date 15 July 2010

International Classifications

A61K 9/52 (2006.01) Medicinal preparations characterised by special physical form - Sustained or differential release type

A61K 9/16 (2006.01) Medicinal preparations characterised by special physical form - Agglomerates

A61K 38/31 (2006.01) Medicinal preparations containing peptides - Somatostatins

A61K 47/10 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Alcohols

A61K 47/26 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Carbohydrates

A61K 47/38 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Cellulose

Event Publications

30 June 2011 PCT application entered the National Phase

  PCT publication WO2010/079047 Priority application(s): WO2010/079047

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009336723-Nanoparticle compositions

2009336711-Recombinant porcine chymotrypsin